Dr. Claudio Andaloro is MD at Department of Surgery, Otolaryngology Unit, Latisana-Palmanova Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy. His research interests focus on rhinology, laryngology, pediatric otolaryngology and sleep medicine.
Professor of Pulmonary Medicine at the Univeristy of Montpellier. Former Director of the INSERM Laboratory for the Immunopathology of Asthma & former chairman of the Global Initiative for Asthma (GINA). Founder & Chairman of ARIA (Allergic Rhinitis & its Impact on Asthma). Chairman of the WHO Global Alliance against Chronic Respiratory Diseases (GARD). Former President of the Societé Française d'Allergologie et d'Immunologie Clinique. Former EiC of the journal Allergy.
Prof. of Immunology and Director of INSERM UMRS 940. Head of the 'Jean Dausset' Histocompatibility & Immunogenetics Laboratory at Saint-Louis Hospital. Former President of the International Histocompatibility council (IHC), former chairman of the 12th International Histocompatibility Workshop & Conference (IHWC) & former President of the European Foundation of Immunogenetics (EFI). Founder President of HLA & Medicine & founding member of the European Institute for System Biology & Medicine.
Head of Section, Allergy and Clinical Immunology at National Heart and Lung Institute, Imperial College and Honorary Consultant Physician in Allergy and Respiratory Medicine at Royal Brompton Hospital London. The immediate Past President of the British Society for Allergy and Clinical Immunology. Member Steering Committee and head of Allergy Consortium, Immune Tolerance Network/NIAID, USA.
I am a biostatistician in the Biostatistics Centre at the University of Otago, a role I have held since 2004. Most of my work involves collaborating on a wide range of research projects in the health sciences, particularly in paediatric obesity, sleep, and physical activity; respiratory epidemiology, mostly asthma and COPD; dentistry; and health systems. I also work on statistical methods research, mostly topics inspired by these collaborations.
Prior to my current position I was a software metrics and machine learning researcher in the Department of Information Science at the same institution.
Jorge Kalil is Professor of Clinical Immunology and Allergy and Director of the Laboratory of Immunology at the Heart Institute (InCor), School of Medicine, University of São Paulo (FMUSP), Brazil. He is Adjunct Professor at the George Washington University, DC, USA, and at the Case Westen University, Cleveland. He represents Latin America in the scientific advisory board of the International Institute of Genetic Engineering and Biotechnology (ICGEB), an UNO Institution since 2013 and a member of the Brazilian Academy of Sciences since 1995. Since 2001, he coordinates iii-Institute for Investigative Immunology, a National Institute linked to the Ministry of Science and Technology, in Brazil. In addition, he co-chairs the Federation of Clinical Immunology Societies - FOCIS Center of Excellence in São Paulo and member of the Council of the USP Pasteur Institute’s board since 2018. He is member of the DSMB/NIH for analyses of phase 3 clinical trials of vaccines anti COVID supported by the US government and board member of COVAX, a WHO/GAVI/CEPI initiative to selecting and buying COVID vaccines to distribute to the world. Kalil graduated in Medicine in Brazil (1977), has a Master’s degree in Immunology and Immunogenetics and is Doctor of Science in Human Biology. He is currently developing vaccines against COVID-19 Streptococcus, HIV, Dengue and Zika in advanced scientific stage.
Main research Interests:
A) Asthma is a major cause of morbidity in the Western world but curative therapies do not exist. Hence, we aim to understand how early life environmental exposures modify lung development development and the risk of developing asthma throughout life. We use animal models of prenatal exposure to tobacco/nicotine products and human samples.
B) The importance of a steady-state balance of resident and non-resident bacterial communities for human health is increasingly appreciated. Yet, factors driving the composition of such microbial communities remain poorly understood. Therefore, we currently investigate the influence of smoke on the structure and functionality of the lung microbiome and its interaction with the lung health.
Currently Funded Projects
2012 – 2016 Chair of COST Action BM1201 “Developmental origins of Chronic Lung Disease” http://www.cost-early-origin-cld.eu/
2013 – 2016 Understanding the role of the lung microbiome for human health and diseases”, HMGU Environmental Health Projects, Co-PI until move to University of Kiel; Project currently continued on a collaborative basis.
Since 2013 – 2018 PI within German Center for Lung Research www.dzl.de
2016 - 2018 Chair of “The lung Microbiota at the Interface between airway epithelium and the environment” funded by the Leibniz Association
Vice President and Head of the Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany. Professor of Food Chemistry, Faculty of Chemical and Pharmaceutical Sciences, Johann Wolfgang Goethe-Universität, Frankfurt/Main, Germany. Member of the European Academy of Allergy and Clinical Immonology. Member of the German Chemical Society and the German Food Chemisty Society. Chairman of the International Union of Immunological Societies Allergen Standardization Subcommittee.